Contents
Key findings
- 1Thymosin beta-4 (Tβ4) is a natural 43-amino-acid peptide; TB-500 is a short synthetic fragment marketed as its active region. Almost all cited research is about Tβ4, not TB-500.
- 2Tβ4 has plausible repair biology (actin regulation, cell migration, angiogenesis) and animal data in skin, cornea and heart models.
- 3Human trials of Tβ4 exist but are small and early: a phase 2 study in venous leg ulcers and trials of Tβ4 eye drops (RGN-259) for dry eye and neurotrophic keratopathy. None has led to approval.
- 4There is no controlled human trial of the TB-500 fragment for any outcome, and no registered trial.
- 5Both are prohibited in sport; TB-500 sold online is an unregulated product of unverified content.
Evidence level
Full-length thymosin beta-4 has animal repair data and small phase 1/2 human trials in venous ulcers, dry eye and neurotrophic keratopathy. The TB-500 fragment sold online has no controlled human trials; its evidence is borrowed from the parent molecule.
Regulatory status
TB-500 is not FDA-approved. Full-length thymosin beta-4 formulations (e.g. RGN-259 eye drops) are investigational in registered trials. Both are prohibited in sport at all times under WADA S2.3 (growth factors).
Search "TB-500 research" and you get a wall of impressive-sounding papers: cardiac repair, corneal healing, wound closure, even hair growth. Read the papers and they are about thymosin beta-4 — a natural 43-amino-acid peptide — and mostly in animals. TB-500 is something else. This analysis sorts out which evidence belongs to which molecule.
The question readers ask
Does TB-500 speed recovery from injury? The answer has two parts. For thymosin beta-4, the full-length peptide, the answer is "plausibly, in animals; unproven in humans; small early trials in wounds and eyes." For TB-500, the fragment sold online, the answer is "no human evidence at all."
Two molecules, one marketing name
Thymosin beta-4 (Tβ4) is a small protein — 43 amino acids, right at the peptide/protein boundary — present in almost every human cell. Its best-understood job is binding G-actin, which makes it a regulator of the cytoskeleton, cell shape and cell migration. Because migration underlies wound closure, angiogenesis and tissue repair, Tβ4 has been studied for decades as a regenerative agent[1].
TB-500 is a synthetic fragment marketed as the "active region" of Tβ4 — usually described as a segment around residues 17–23 (LKKTETQ), sometimes with modifications. Commercial products are not standardised, so what "TB-500" contains can vary by seller. Crucially, the assumption that a seven-residue fragment does in a human what a 43-residue protein does in a mouse has never been tested in a controlled study.
What the thymosin beta-4 research shows
Animal models. Tβ4 accelerates dermal wound closure in rodents, improves corneal healing after injury, and in mouse myocardial infarction models has been reported to promote cardiomyocyte survival and vessel growth. These are the studies most often quoted for TB-500.
Human trials. Tβ4 has been in registered clinical trials for years[4], mostly sponsored by one developer (RegeneRx and partners):
- Venous leg ulcers. A European phase 2 randomised placebo-controlled study of topical Tβ4 in 72 patients found it well tolerated, with a healing signal at the middle dose but no clean dose-response[2]. It was not followed by a confirmatory phase 3.
- Dry eye. A phase 2 trial of Tβ4 eye drops (RGN-259) in 72 patients reported improvements in some signs and symptoms versus placebo, with mixed primary results[3]; later, larger trials followed with similarly mixed outcomes.
- Neurotrophic keratopathy. Tβ4 drops have been studied in this rare corneal condition, with phase 3 work ongoing or reported at various points.
Study details: Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement in healing
- Study type
- Randomised, placebo-controlled phase 2
- Population
- Adults with chronic venous leg ulcers
- Sample size
- 72
- Primary result
- Topical Tβ4 well tolerated; healing signal at a middle dose; not dose-linear.
- Limitations
- Small; secondary efficacy signal; not confirmed in a phase 3.
- Year
- 2010
- Source
- Annals of the New York Academy of Sciences(link not yet independently re-verified)
Notice what these are: small, early-phase, topical or ophthalmic, in specific conditions, funded by the developer, and not yet successful enough for approval. That is a real research programme — and it is nowhere near "TB-500 heals your torn hamstring".
What the TB-500 research shows
We could not identify a single controlled human trial of the TB-500 fragment for any outcome, nor a registered trial. Its use appears to have originated in horse racing (where it is also banned) and moved into human grey markets on the strength of Tβ4's animal data. Vendors' citations, when traced, lead to Tβ4 papers.
That means the evidence grade for TB-500 in humans is preclinical, and generously so: it inherits Tβ4's animal plausibility without any direct test.
Safety: the difference between "well tolerated in a trial" and "no data"
Tβ4 formulations were reported as well tolerated in early-phase trials — a modest reassurance that applies to those formulations, doses and routes. For the injected TB-500 fragment there are no human safety data of any kind. Two theoretical concerns follow from the mechanism: a molecule that promotes cell migration and angiogenesis is one whose behaviour around tumours needs studying, and immunogenicity of synthetic fragments is unknown. Add the product-quality problem common to all grey-market peptides (see our certificate-of-analysis analysis) and the safety picture is simply blank.
Regulatory position
Neither TB-500 nor thymosin beta-4 is FDA-approved. Tβ4 formulations are investigational in registered trials. TB-500 is not. Both are prohibited in sport at all times under WADA's S2.3 (growth factors), which names thymosin-β4 and its derivatives such as TB-500[5].
Grades by claim
| Claim | Molecule actually studied | Best evidence | Grade |
|---|---|---|---|
| Speeds healing of chronic wounds | Tβ4 (topical) | Phase 2 RCT, n=72, mixed | Preliminary evidenceSmall early human trial |
| Improves dry eye / corneal healing | Tβ4 (eye drops) | Phase 2/3 RCTs, mixed | Preliminary evidenceHuman trials, inconsistent |
| Repairs heart tissue | Tβ4 | Mouse MI models | Preclinical evidenceAnimal only |
| Heals tendon/muscle injury | TB-500 (marketing) / Tβ4 (animal) | No human trial | Preclinical evidenceNo direct evidence |
| TB-500 does what Tβ4 does | TB-500 | None | Unsupported evidenceUntested assumption |
Where to go next
- TB-500 profile — summary, FAQ and key studies.
- BPC-157 vs TB-500 — how the two "healing peptides" compare on evidence and regulation.
- Recovery and tissue repair hub.
Frequently asked questions
- Is TB-500 just thymosin beta-4 under another name?
- No. Thymosin beta-4 is the full 43-amino-acid peptide. TB-500 is a much shorter synthetic fragment. Human trial data exist only for the full-length molecule.
- Has thymosin beta-4 been approved for anything?
- Not in the U.S. Formulations have reached phase 2/3 trials for eye conditions and phase 2 for wounds, without approval so far.
- Why do vendors cite heart and wound studies for TB-500?
- Because those studies exist — for thymosin beta-4, mostly in animals. The leap from full-length Tβ4 in a mouse to a fragment in a person is not supported by any trial.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications Expert Opinion on Biological Therapy, 2012.
Review
Result: Reviews Tβ4 biology, animal repair models and early clinical trials.
Limitations: Authors have commercial interests in Tβ4 development.
↑ back to text - 2.
Guarnera G, DeRosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement in healing Annals of the New York Academy of Sciences, 2010.
Randomized controlled trialAdults with chronic venous leg ulcersn = 72
Result: Topical Tβ4 well tolerated; healing signal at a middle dose; not dose-linear.
Limitations: Small; secondary efficacy signal; not confirmed in a phase 3.
↑ back to text - 3.
Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE) model Clinical Ophthalmology, 2015.
Randomized controlled trialAdults with dry eyen = 72
Result: Improvements in some sign and symptom measures vs placebo; primary endpoints mixed.
Limitations: Small; sponsor-run; mixed primary results.
↑ back to text - 4.
Clinical trials of thymosin beta 4 (search) ClinicalTrials.gov.
Trial registry
Result: Registered trials of Tβ4 formulations; none of the TB-500 fragment.
↑ back to text - 5.
The Prohibited List World Anti-Doping Agency, 2026.
Regulatory source
Result: Thymosin-β4 and its derivatives (e.g. TB-500) named under S2.3 Growth Factors; prohibited at all times.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
